Global Drugs of Ursodeoxycholic Acid Market Size By Type (Capsule, Tablet), By Application (Gallstone, Hepatopathy), By Region, And Segment Forecasts, 2023 to 2032

The Global Drugs of Ursodeoxycholic Acid Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 1.8 billion by 2031, growing at a CAGR of 6.4% during the forecast period from 2023 to 2031. Ursodeoxycholic acid (UDCA) drugs are primarily used to dissolve gallstones and treat primary biliary cholangitis (PBC) and other cholestatic liver diseases. Rising prevalence of liver-related conditions, increasing geriatric population, and growing awareness about hepatoprotective therapies are key drivers propelling the global UDCA drugs market.

Drivers:

Rising Prevalence of Liver Diseases:

The global burden of liver diseases such as primary biliary cirrhosis, gallstones, and non-alcoholic fatty liver disease (NAFLD) is significantly increasing. UDCA has demonstrated effectiveness in reducing liver enzyme levels and improving liver function, making it a preferred treatment option.

Increased Awareness and Early Diagnosis:

Awareness campaigns and improved diagnostic tools are leading to earlier detection of liver conditions. This supports higher treatment rates and fuels demand for UDCA-based pharmaceuticals.

Geriatric Population Growth:

Older individuals are more susceptible to liver dysfunctions and gallstone formation, increasing the need for UDCA-based drugs to manage these conditions effectively.

Restraints:

Availability of Alternative Therapies:

Newer therapeutic options and lifestyle interventions may substitute UDCA treatments in certain cases, limiting its market expansion.

Stringent Regulatory Approvals:

Being a specialty drug, UDCA formulations require strict clinical validation and regulatory approvals, which can pose hurdles for market entry, especially for generic players.

Opportunity:

Expansion in Emerging Markets:

Emerging economies in Asia-Pacific, Latin America, and parts of Africa represent untapped markets where liver disease burden is high and healthcare access is improving. Pharmaceutical companies are expanding into these regions, creating growth avenues.

Research and Formulation Development:

Ongoing R&D efforts aimed at enhancing UDCA formulations for improved bioavailability and combination therapies are expected to unlock new opportunities.

Market by System Type Insights:

Based on system type, Tablet formulations held the dominant market share in 2023, attributed to their ease of administration and patient compliance. The Capsule segment is also witnessing substantial growth due to its adoption in chronic treatment protocols, especially for gallstone dissolution.

Market by End-use Insights:

In 2023, Hospitals and Clinics emerged as the largest end-use segment, driven by the increasing number of in-patient treatments for liver disorders. Meanwhile, Retail Pharmacies are expected to register notable growth during the forecast period, benefiting from improved drug accessibility and growing OTC demand in some regions.

Market by Regional Insights:

North America dominated the global UDCA drugs market in 2023, supported by robust healthcare infrastructure, early diagnosis rates, and high adoption of specialty pharmaceuticals. However, Asia-Pacific is projected to be the fastest-growing region, driven by increasing liver disease prevalence, rising health awareness, and growing pharmaceutical industry investments in countries like India and China.

Competitive Scenario:

Leading players in the Global Drugs of Ursodeoxycholic Acid Market include Dr. Reddy’s Laboratories, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma, Teva Pharmaceuticals, Cadila Healthcare, and Apotex Inc. These companies are focusing on cost-effective formulations, regional expansion, and strategic collaborations. For instance:

In 2023, Dr. Reddy’s launched a new UDCA 300mg tablet for the European market, expanding its hepatology portfolio.

Zydus Lifesciences received regulatory approval in 2024 to market a generic UDCA formulation in Southeast Asia.

Sun Pharma partnered with a regional distributor in 2025 to expand access to UDCA drugs across Latin America.

Scope of Work – Global Drugs of Ursodeoxycholic Acid Market

Key Market Developments:

2023: Mitsubishi Tanabe Pharma introduced a modified-release UDCA formulation in Japan, improving patient adherence through reduced dosing frequency.

2024: Apotex Inc. secured marketing authorization for its UDCA capsule in the Middle East and North Africa (MENA) region.

2025: Teva Pharmaceuticals announced the expansion of its UDCA production facility in Canada to meet rising global demand.

FAQs:

What is the current market size of the Global Drugs of Ursodeoxycholic Acid Market?

The market was valued at USD 1.1 billion in 2023.

What is the major growth driver of the Global Drugs of Ursodeoxycholic Acid Market?

The increasing prevalence of liver diseases and growing demand for hepatoprotective drugs are key growth drivers.

Which is the largest region during the forecast period in the Global Drugs of Ursodeoxycholic Acid Market?

North America held the largest market share in 2023.

Which segment accounted for the largest market share in the Global Drugs of Ursodeoxycholic Acid Market?

Tablet formulations accounted for the largest share by system type.

Who are the key market players in the Global Drugs of Ursodeoxycholic Acid Market?

Key players include Dr. Reddy’s Laboratories, Zydus Lifesciences, Sun Pharmaceutical, Teva Pharmaceuticals, and Mitsubishi Tanabe Pharma.